Anti-emetic prophylaxis with oral tropisetron and/or dexamethasone.

Department of Anaesthesiology and Intensive Care, University Hospital Giessen-Marburg, Marburg, Germany.
European Journal of Clinical Investigation (Impact Factor: 2.83). 09/2006; 36(8):580-7. DOI: 10.1111/j.1365-2362.2006.01671.x
Source: PubMed

ABSTRACT The corticosteroid dexamethasone and the serotonine3 -antagonist tropisetron are both effective drugs for the prophylaxis of post-operative nausea and vomiting (PONV) when given intravenously. The aim of this trial was to evaluate the oral use of both drugs as part of a routine oral premedication and to compare their single and combined effectiveness.
In this randomized, placebo-controlled, double-blind study, 320 inpatients with a moderate-high risk of PONV (> or = 40% according to two validated risk scores) received an oral premedication 1-2 h pre-operatively with placebo, a fixed dose of tropisetron 5 mg, dexamethasone 8 mg, or a combination of both drugs. A standardized general anaesthesia was performed, including benzodiazepine premedication, propofol, rocuronium, desflurane in air/O2, fentanyl or sufentanil followed by a continuous infusion of remifentanil. Post-operative analgesia and anti-emetic rescue medication were standardized. The main outcome measures were the severity of PONV within the first 24 h (rated by a standardized scoring algorithm). The incidence of PONV was used as the secondary outcome.
Data from 310 patients were analyzed. The mean severity score in the placebo-, tropisetron-, dexamethasone- and the combined-groups was 1.37, 0.8, 0.8 and 0.38, respectively. The incidence of PONV of any severity was 59.2%, 37.5%, 40% and 22.8%, respectively. The reduction of the incidence and the severity of PONV were statistically significant with all three interventions. Results from additional analyses suggested that both drugs were equally effective and that there was a simple additive effect of tropisetron and dexamethasone compared with placebo.
Oral tropisetron and dexamethasone were both equally effective in reducing the severity and incidence of post-operative nausea and vomiting. The latter could be reduced by approximately 35% in a population of moderate-high risk for PONV. Both drugs had an additive effect. However, even in the combination group there still remained an unacceptably high incidence of PONV of more than 20%. This highlighted the need for a multimodal anti-emetic approach in high-risk patients and the importance of treatment of PONV.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Complete demethylation of Cp2Ti(CH3)2 in dichloromethane with 2 M equivalent of [η5-(C5H4COOH)]Cr(CO)2NO (5), [η5-(C5H4COOH)]Cr(NO)2X] (X = Cl 6, X = I 7), and [η5-(C5H4COOH)]W(CO)3CH3 (8); gives Cp2Ti{[OC(O)C5H4]Cr(CO)2NO}2 (13), Cp2Ti{[OC(O)C5H4]Cr(NO)2Cl}2 (14), Cp2Ti{[OC(O)C5H4]Cr(NO)2I}2 (15),and Cp2Ti{[OC(O)C5H4]W(CO)3CH3}2 (16), respectively. The chemical shifts of C(2)–C(5) carbon atoms of compounds 13–15 have been assigned using two-dimensional HetCOR NMR spectroscopy. The assigned chemical shifts were compared with the NMR data of their analogues of ferrocene, and the opposite correlation on the assignments was observed for cynichrodenoyl moieties.
    Journal of Organometallic Chemistry 05/2011; 696(10):2065–2070. DOI:10.1016/j.jorganchem.2010.11.001 · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present guidelines are the most recent data on postoperative nausea and vomiting (PONV) and an update on the 2 previous sets of guidelines published in 2003 and 2007. These guidelines were compiled by a multidisciplinary international panel of individuals with interest and expertise in PONV under the auspices of the Society for Ambulatory Anesthesia. The panel members critically and systematically evaluated the current medical literature on PONV to provide an evidence-based reference tool for the management of adults and children who are undergoing surgery and are at increased risk for PONV. These guidelines identify patients at risk for PONV in adults and children; recommend approaches for reducing baseline risks for PONV; identify the most effective antiemetic single therapy and combination therapy regimens for PONV prophylaxis, including nonpharmacologic approaches; recommend strategies for treatment of PONV when it occurs; provide an algorithm for the management of individuals at increased risk for PONV as well as steps to ensure PONV prevention and treatment are implemented in the clinical setting.
    Anesthesia and analgesia 01/2014; 118(1):85-113. DOI:10.1213/ANE.0000000000000002 · 3.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: New antiemetic drug developments, formulations, guidelines, risk evaluation, and controversies have occurred in the area of postoperative nausea and vomiting (PONV). These developments have helped improve our understanding of the prevention and treatment of PONV in the postanesthesia care unit and after discharge home or to the hospital ward. Antiemetic drug research has resulted in the introduction of the second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron and the neurokinin-1 (NK-1) receptor antagonist aprepitant, as well as new data on existing antiemetics. The next frontier and need for further nausea and vomiting research and therapy is the area of postdischarge nausea and vomiting after the patient is discharged home from phase II of the ambulatory stepdown unit or to the hospital ward. Antiemetic drug selection depends on efficacy, cost, safety, and ease of dosing. Safety concerns have arisen regarding the side effects of antiemetics, specifically their effect on the ECG with prolongation of the QTc interval by the butyrophenones and the first-generation 5-HT3 receptor antagonist class of antiemetics. The impact of pharmocogenetics on antiemetic drug metabolism and their resulting efficacy has been correlated with genetic makeup affecting drug response. A discussion of ethics in PONV research has been initiated by the meta-analysis of PONV studies. To help guide antiemetic selection and PONV therapy for clinical practitioners, the Society of Ambulatory Anesthesia (SAMBA) PONV consensus guidelines have been introduced and updated.
    Drugs 09/2013; DOI:10.1007/s40265-013-0110-7 · 4.13 Impact Factor